Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial

By sjmartinez • February 2, 2023

Baksh S, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton J, Mosnaim G, Anjan S, Blair J, Cachay E, Currier J, Das P, Huaman M, Sutcliffe C, Yarava A, Casadevall A, Sullivan D, Hanley D, Gebo KA; CSSC-004 Consortium. Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial. J Infect Dis. 2023 Jan 31:jiad023. doi: 10.1093/infdis/jiad023. Epub ahead of print. PMID: 36722044.

Tags: covid-19, COVID-19 serotherapy, Infectious Diseases, plasma, Publications, Symptom duration

A spatial transcriptomic atlas of the host response to oropharyngeal candidiasis

Nabeela S, McSwiggin H, Magalhaes RDM, Mattos EC, Mannan M, Dillon JT, Barbarino A, Youssef EG, Singh S, Yan W, Ibrahim AS, Conti HR, Uppuluri[...]

Strain background interacts with chromosome 7 aneuploidy to determine commensal and virulence phenotypes in Candida albicans

Mishra A, Solis NV, Dietz SM, Crouch AL, Filler SG, Anderson MZ. Strain background interacts with chromosome 7 aneuploidy to determine commensal and virulence phenotypes[...]

Preexposure Prophylaxis for HIV: Updated Recommendations From the 2024 International Antiviral Society-USA Panel

Landovitz RJ, Molina JM, Buchbinder SP; International Antiviral Society-USA (IAS-USA) Panel. Preexposure Prophylaxis for HIV: Updated Recommendations From the 2024 International Antiviral Society-USA Panel. JAMA.[...]